Control of hepatitis B in China: prevention and treatment

References

• Xia GL, Liu CB, Cao HL et al. Prevalence of hepatitis B and C virus infections in the general Chinese population: results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China, 1992. Int. Hepatol. Commun.5(1), 62–73 (1996).
   Web of Science ®Google Scholar
• Liang X, Bi S, Yang W et al. Epidemiological serosurvey of hepatitis B in China – declining HBV prevalence due to hepatitis B vaccination. Vaccine27(47), 6550–6557 (2009).
   PubMed Web of Science ®Google Scholar
• Chen J, Jia JD. Treatment of viral hepatitis in China: better clinical research and improved practice. Chin. Med. J.122(19), 2236–2238 (2009).
   PubMed Web of Science ®Google Scholar
• Liang XF, Bi SL, Yang WZ et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J. Infect. Dis.200(1), 39–47(2009).
   PubMed Web of Science ®Google Scholar
• Xia GL, Liu CB, Yan TQ et al. Prevalence of hepatitis B virus markers in children vaccinated by hepatitis B vaccine in five areas of China. Chin. J. Exp. Clin. Virol.9(Suppl.), 17–23 (1995).
   Google Scholar
• Li H, Li RC, Liao SS et al. Long-term persistence of immunological memory for HBsAg after initial hepatitis B vaccine immunoprophylaxis. Chin. Med. Sci. J.14(Suppl.), 17–20 (1999).
   PubMedGoogle Scholar
• Li RC, Yang JY, Wang SS et al. 10 year follow-up on hepatitis B virus markers in the population after hepatitis B vaccination. Chin. J. Exp. Clin. Virol.9(Suppl.), 32–36 (1995).
   Google Scholar
• Xia GL, Jia ZY, Yan TQ et al. Long term efficacy and persistence of anti-HBs in infants after receiving plasma derived hepatitis B vaccine alone. Chin. J. Exp. Clin. Virol.16(2), 146–149 (2002).
   Google Scholar
• Li RC, Yang JY, Gong J et al. Efficacy of hepatitis B vaccination for prevention of hepatocellular carcinoma in an endemic area of China. Chin. J. Epidemiol.25(5), 385–387 (2004).
   Google Scholar
• Chen YS, Liang XF, Chen LJ et al. Sero-epidemiological study on hepatitis B in Chinese children. Chin. J. Vaccine Immun.12(2), 84–87 (2006).
   Google Scholar
• Liang ZL, Li HM. A study on the cost-effectiveness of hepatitis B vaccine immunization on different populations in China. Chin. J. Biol.19(4), 434–436 (2006).
   Google Scholar
• Shang G, Seed CR, Wang F, Nie DM, Albert F. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion47(3), 529–539 (2007).
   PubMed Web of Science ®Google Scholar
• Liang XF, Chen YS, Wang XJ et al. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old. Chin. J. Epidemiol.26(9), 655–658 (2005).
   Google Scholar
• Parry J. Viral hepatitis appears on World Health Assembly agenda for first time. Br. Med. J.340(5), c2420 (2010).
   Google Scholar
• Xu WM, Cui YT, Wang L et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J. Viral. Hepat.16(2), 94–103 (2009).
   PubMed Web of Science ®Google Scholar
• Yao G, Wang B, Cui Z, Yao J, Zeng M. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin. Med. J.112(5), 387–391 (1999).
   PubMed Web of Science ®Google Scholar
• Zeng M, Mao Y, Yao G et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology44(1), 108–116 (2006).
   PubMed Web of Science ®Google Scholar
• Yao G, Chen C, Lu W et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol. Int.2(4), 486–493 (2008).
   PubMed Web of Science ®Google Scholar
• Hou J, Yin YK, Xu D et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology47(27), 447–454 (2008).
   PubMed Web of Science ®Google Scholar
• Shi M, Wang RS, Zhang H et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J. Antimicrob. Chemother.58(5), 1031–1035 (2006).
   PubMed Web of Science ®Google Scholar
• Zhao H, Kurbanov F, Wan MB et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin. Infect. Dis.44(4), 541–548 (2007).
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med.357(25), 2576–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology136(2), 486–495 (2009).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.351(12), 1206–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.352(26), 2682–2695 (2005).
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hepatology and Chinese Society of Infectious Diseases. Guideline on the prevention and treatment of chronic hepatitis B. Chin. J. Hepatol.13(12), 881–891 (2005).
   PubMedGoogle Scholar
• Chinese Society of Hepatology and Chinese Society of Infectious Diseases. Guideline on the prevention and treatment of chronic hepatitis B. Chin. Med. J.120(24), 2159–2173 (2007).
   PubMed Web of Science ®Google Scholar
• Jia JD. Hepatitis B in China: from guideline to practice. Virologica Sinca.23(2), 152–155 (2008).
   Google Scholar
• Jia JD, Zhuang H. A winning war against hepatitis B virus infection in China. Chin. Med. J.120(24), 2157–2158 (2007).
   PubMed Web of Science ®Google Scholar